Testing ORKA-001 for moderate-to-severe plaque psoriasis
Part of Skin clinical trials.
This study tests an investigational drug called ORKA-001 in people with moderate-to-severe plaque psoriasis. It aims to find the best dose and see if it clears skin and reduces symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have had plaque psoriasis for more than 6 months
- Have moderate-to-severe psoriasis covering at least 10% of your body
- Be a candidate for systemic treatment or light therapy
- Not be pregnant, breastfeeding, or planning to become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called ORKA-002 for people with moderate-to-severe plaque psoriasis. It aims to see how well different doses work and if they are safe. You may qualify if your psoriasis covers at least 10% of your body or if it has not responded well enough to other treatments.
This study is a continuation for people who already took ORKA-001 for plaque psoriasis and did well. It tests whether staying on the medicine keeps helping without any new safety concerns.
This early-phase study tests an experimental oral tablet (UA026) in people with moderate to severe plaque psoriasis. The purpose is to see how safe and effective the drug is, and how it works in the body.
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
This study tests a new oral pill (HSK47388) for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective in reducing the severity and area of psoriasis over 12 weeks.
This study tests an experimental oral medication (a TYK2 inhibitor) for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing psoriasis symptoms.
Hear when a new Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.